Keyphrases
Advanced Biliary Tract Cancer
100%
Adverse Events
33%
Clinical Outcomes
100%
Combination Chemotherapy
100%
Efficacy Analysis
16%
Elderly Patients
100%
Elderly People
100%
Gemcitabine Plus Cisplatin
50%
Gemcitabine Plus S-1
66%
Hematological Adverse Events
16%
Influence of Age
16%
Median Overall Survival
16%
Non-elderly
50%
Non-inferiority
16%
Nonelderly Patients
16%
Overall Survival
50%
Safety Analysis
16%
Subgroup Analysis
16%
Medicine and Dentistry
Adverse Event
42%
Arm
28%
Biliary Tract Cancer
100%
Cisplatin
42%
Combination Chemotherapy
100%
Elderly Patient
100%
Gemcitabine
100%
Overall Survival
57%
Prevalence
14%
Subgroup Analysis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
42%
Biliary Tract Cancer
100%
Chemotherapy
100%
Cisplatin
42%
Gemcitabine
100%
Overall Survival
57%
Prevalence
14%
Agricultural and Biological Sciences
Biliary Tract
100%
Prevalence
25%